Vetigenics is a clinical-stage animal health biopharmaceutical company developing targeted antibody therapeutics for companion animals using its proprietary CANIBODY™ discovery platform. The company is advancing antibody-based treatments across oncology and non-oncology areas, including autoimmune disease, obesity, and allergy. It announced a $6 million seed financing to accelerate clinical-stage programs, push preclinical candidates forward, and scale operations and manufacturing. Two canine cancer programs—VGS-001 (anti-cCTLA4) and VGS-002 (anti-cPD1)—have reached key milestones with encouraging results expected in 2025, and VGS-003 (anti-cCD19 mAb) is on track to enter clinical trials by the end of 2025. Vetigenics has established a board of directors composed of industry leaders to guide growth and highlighted collaborations with global animal health partners and the National Cancer Institute. The company plans to use the new funding to advance programs toward pivotal trials and expand its development and manufacturing capabilities.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2025